700
Participants
Start Date
November 26, 2021
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Cabotegravir/ Rilpivirine
"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
Etonogestrel (ETG) implant
Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
Levonorgestrel
Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
RECRUITING
Academic Model Providing Access to Healthcare (AMPATH) Moi Teaching And Referral Hospital (MTRH), Eldoret
Moi Teaching and Referral Hospital
OTHER
Indiana University
OTHER
University of Nebraska
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of Alabama at Birmingham
OTHER